ImpedimedASX:IPD PS Ratio is 0.71 as of Jun. 28, 2026, which is 95% below its 10-year median of 15.11. The stock has 6 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Impedimed ranks better than 86.21% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Impedimed's share price is A$0.005.
Impedimed's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.01. Hence, Impedimed's PS Ratio for today is 0.71.
Good Sign:
Impedimed Ltd stock PS Ratio (=0.83) is close to 10-year low of 0.83.
The historical rank and industry rank for Impedimed's PS Ratio or its related term are showing as below:
ASX:IPD'
s PS Ratio Range Over the Past 10 Years
Min: 0.71 Med: 15.11 Max: 98.79
Current: 0.71
During the past 13 years, Impedimed's highest PS Ratio was 98.79. The lowest was 0.71. And the median was 15.11.
ASX:IPD's PS Ratio is ranked better than 86.21% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.87
vs ASX:IPD: 0.71
Impedimed Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Impedimed was 16.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -9.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -12.40% per year.
During the past 13 years, Impedimed's highest 3-Year average Revenue per Share Growth Rate was 6.70% per year. The lowest was -22.40% per year. And the median was -12.10% per year.
Back to Basics: PS Ratio
Impedimed (ASX:IPD) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Impedimed PS Ratio Related Terms
Impedimed PS Ratio Historical Data
* Premium members only.
The historical data trend for Impedimed's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Impedimed's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Impedimed PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Impedimed's PS Ratio distribution charts can be found below:
* The bar in red indicates where Impedimed's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Impedimed's Share Price of today is A$0.005.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Impedimed's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Impedimed (ASX:IPD) has a PS Ratio of 0.71 as of Jun. 28, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Impedimed and its competitors. This is 95% below median its historical median of 15.11. Over the past decade, Impedimed's PS Ratio has ranged from 0.71 to 98.79. According to the industry distribution chart, Impedimed ranks #111 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 13.8%.
Is Impedimed's PS Ratio too high?
Impedimed's current PS Ratio of 0.71 is 95% below median its 10-year median of 15.11. Over the past 10 years, this metric has ranged from a low of 0.71 to a high of 98.79. The Medical Devices & Instruments industry median PS Ratio is 2.87. Impedimed's value of 0.71 is 75.3% below this industry median. Based on the distribution chart, Impedimed ranks #111 out of 805 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Impedimed's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Impedimed ranks #111 out of 805 companies for PS Ratio. This places Impedimed in the top 14% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.87. Impedimed's value of 0.71 is 75.3% below this benchmark. Historically, Impedimed's own PS Ratio has ranged from 0.71 to 98.79 over the past decade. While the company's 10-year median is 15.11 vs. the industry median of 2.87, Impedimed has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.87, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Impedimed's current PS Ratio of 0.71 is 75.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Impedimed and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Impedimed's current PS Ratio is 0.71, which is 95% below median its own 10-year median of 15.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impedimed stock overvalued right now?
Based on GuruFocus' analysis, Impedimed (ASX:IPD) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.08, compared to a current price of A$0.01 — trading 93.8% below its estimated fair value. The current PS Ratio is 0.71, which is 95% below median its 10-year median of 15.11 and 75.3% below the Medical Devices & Instruments industry median of 2.87. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Impedimed (ASX:IPD), the current PS Ratio is 0.71 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IPD has been successfully added to your 